2020 Marks a Year of Achievement
As 2020 draws to a close, C₂N Diagnostics is pleased to issue our first e-newsletter to share news and updates on the PrecivityAD™ test. The test is the first widely accessible blood test in the U.S. that physicians are using to aid in the Alzheimer’s disease evaluation process.
Read About the Blood Test
The Associated Press reported the story of Tammy Maida, who said the PrecivityAD™ blood test would have saved her a decade of “futile trips to doctors who chalked up her symptoms to depression, anxiety or menopause before a $5,000 brain scan last year finally showed she had Alzheimer’s.”
Maida said, if the blood test had been available, “I might have been afraid of the results” but would have “jumped on that” to find out.
Read More
Dr. Karen Abrashkin, a medical director with Northwell Health, explained to CBS News that the PrecivityAD™ blood test is an advancement because it allows physicians to rule in or rule out Alzheimer’s disease as a likely cause of illness for people who are showing signs of cognitive impairments.
Watch Video
Other reports highlighted how the PrecivityAD™ blood test “costs about 75% less than current brain scans.” Fox News in Houston reported that Dr. Paul Schulz, a neurologist with UT Health, said,
“I think the value of this test is that it's telling us we're getting close. We can now measure the pathological protein.”
Read More
Fox News in St. Louis visited the lab and shared the excitement about this breakthrough with its viewers.
Watch Video
Two other developments are also enabling expanded access of C₂N’s test for patients within the U.S. and internationally. The first update is that C₂N’s laboratory recently received its CLIA certificate from the state of California. With this latest certification, this means that C₂N can offer the test in 46 states, the District of Columbia and Puerto Rico.
The PrecivityAD™ blood test has also achieved the CE Mark from the European Union (EU); this means this unique mass spectrometry-based blood test is commercially available in the EU.
For new news and updates, please visit https://precivityad.com.
In 2021, we look forward to more achievements, including publication of research in peer-reviewed journals and U.S. Food & Drug Administration review of the PrecivityAD™ blood test.
Most of all, we send you best wishes for a safe and healthy holiday season.